Biokine Therapeutics Ltd. (Biokine) is a clinical-stage biopharmaceutical company developing novel drugs to treat cancer.
Biokine is devoted to identifying novel molecular and cellular mechanisms that regulate tumor development and metastasis. Founded in 2000 by Prof. Amnon Peled, a leading cancer and stem cell biologist at Hadassah University Hospital, Biokine has completed more than 14 years of R&D and clinical research.
Biokine has developed a suite of unique approaches to target cancer and is conducting preclinical and clinical research on several molecules discovered and developed in-house. Biokine’s lead drug candidate, the high-affinity CXCR4 antagonist BKT140/BL8040, is currently in Phase IIa clinical trial for the treatment of refractory and relapsed Acute Myeloid Leukemia (AML), as well as a Phase I clinical trial for the mobilization of stem cells. The CXCR4 receptor plays a pivotal role in the regulation of certain cancers and inflammatory diseases and is critically involved in stem cell biology and tissue regeneration. BKT140/BL8040 was licensed to BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) for further clinical and market development in 2012.
Biokine has a unique knowhow, technologies, and a pipeline for the development of therapeutics targeting cancer. Biokine intends to advance the development of its pipeline into the clinic by establishing collaborations with other companies and conducting fundraising activities from private and public agencies.